FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency
FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency
Our functional genomic RNAi screens have identified the protein components of the FACT (facilitates chromatin transcription) complex, SUPT16H and SSRP1, as top host factors that negatively regulate HIV-1 replication. FACT interacts specifically with histones H2A/H2B to affect assembly and disassembly of nucleosomes, as well as transcription elongation. We further investigated the suppressive role of FACT proteins in HIV-1 transcription. First, depletion of SUPT16H or SSRP1 protein enhances Tat-mediated HIV-1 LTR (long terminal repeat) promoter activity. Second, HIV-1 Tat interacts with SUPT16H but not SSRP1 protein. However, both SUPT16H and SSRP1 are recruited to LTR promoter. Third, the presence of SUPT16H interferes with the association of Cyclin T1 (CCNT1), a subunit of P-TEFb, with the Tat-LTR axis. Removing inhibitory mechanisms to permit HIV-1 transcription is an initial and key regulatory step to reverse post-integrated latent HIV-1 proviruses for purging of reservoir cells. We therefore evaluated the role of FACT proteins in HIV-1 latency and reactivation. Depletion of SUPT16H or SSRP1 protein affects both HIV-1 transcriptional initiation and elongation and spontaneously reverses latent HIV-1 in U1/HIV and J-LAT cells. Similar effects were observed with a primary CD4+ T cell model of HIV-1 latency. FACT proteins also interfere with HTLV-1 Tax-LTR-mediated transcription and viral latency, indicating that they may act as general transcriptional suppressors for retroviruses. We conclude that FACT proteins SUPT16H and SSRP1 play a key role in suppressing HIV-1 transcription and promoting viral latency, which may serve as promising gene targets for developing novel HIV-1 latency-reversing agents.
- Brigham and Women's Faulkner Hospital United States
- Harvard University United States
- Roswell Park Cancer Institute United States
- University of Rochester United States
- University of Rochester Medical Center United States
CD4-Positive T-Lymphocytes, Human T-lymphotropic virus 1, Cyclin T, High Mobility Group Proteins, 610, Cell Cycle Proteins, Models, Biological, Cell Line, Virus Latency, DNA-Binding Proteins, HEK293 Cells, Host-Pathogen Interactions, HIV-1, Humans, Positive Transcriptional Elongation Factor B, RNA Interference, Transcriptional Elongation Factors, Promoter Regions, Genetic, HIV Long Terminal Repeat, Transcription Factors
CD4-Positive T-Lymphocytes, Human T-lymphotropic virus 1, Cyclin T, High Mobility Group Proteins, 610, Cell Cycle Proteins, Models, Biological, Cell Line, Virus Latency, DNA-Binding Proteins, HEK293 Cells, Host-Pathogen Interactions, HIV-1, Humans, Positive Transcriptional Elongation Factor B, RNA Interference, Transcriptional Elongation Factors, Promoter Regions, Genetic, HIV Long Terminal Repeat, Transcription Factors
11 Research products, page 1 of 2
- 2013IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2020IsAmongTopNSimilarDocuments
- 2019IsAmongTopNSimilarDocuments
- 2016IsAmongTopNSimilarDocuments
- 2011IsAmongTopNSimilarDocuments
- 2019IsAmongTopNSimilarDocuments
chevron_left - 1
- 2
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).43 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
